Disparities in positive results and dissemination of randomized controlled trials in immuno-oncology

References

• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. doi:10.1038/nrc3239.
   PubMed Web of Science ®Google Scholar
• Tang J, Pearce L, O’Donnell-Tormey J, Hubbard-Lucey VM. Trends in the global immuno-oncology landscape. Nat Rev Drug Discov. 2018;17(12):922. doi:10.1038/nrd.2018.202.
   PubMed Web of Science ®Google Scholar
• Dickersin K, Rennie D. Registering clinical trials. JAMA. 2003;290(4):516–523. doi:10.1001/jama.290.4.516.
   PubMed Web of Science ®Google Scholar
• Xu C, Zhang S, Zhang Y, et al. Evolving landscape and academic attitudes toward the controversies of global immuno-oncology trials. Int J Cancer. 2021;149(1):108–118. doi:10.1002/ijc.33503.
   PubMed Web of Science ®Google Scholar
• Dickersin K, Min YI, Meinert CL. Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards. JAMA. 1992;267(3):374–378.
   PubMed Web of Science ®Google Scholar
• Dickersin K, Rothstein H, Sutton A, Borenstein M. Publication Bias: recognizing the Problem, Understanding Its Origins and Scope, and Preventing Harm. Handbook of Publication Bias. Wiley. New York. 2004.
   Google Scholar
• Tonks A. A clinical trials register for Europe. BMJ. 2002;325(7376):1314–1315. doi:10.1136/bmj.325.7376.1314.
   PubMedGoogle Scholar
• DeVito NJ, Bacon S, Goldacre B. Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study. Lancet. 2020;395(10221):361–369. doi:10.1016/S0140-6736(19)33220-9.
   PubMed Web of Science ®Google Scholar
• Chen R, Desai NR, Ross JS, et al. Publication and reporting of clinical trial results: cross sectional analysis across academic medical centers. BMJ. 2016;352:i637. doi:10.1136/bmj.i637.
   PubMed Web of Science ®Google Scholar
• Ramsey S, Scoggins J. Commentary: practicing on the tip of an information iceberg? Evidence of underpublication of registered clinical trials in oncology. Oncologist. 2008;13(9):925–929. doi:10.1634/theoncologist.2008-0133.
   PubMed Web of Science ®Google Scholar
• Unger JM, Barlow WE, Ramsey SD, LeBlanc M, Blanke CD, Hershman DL. The scientific impact of positive and negative phase 3 cancer clinical trials. JAMA Oncol. 2016;2(7):875–881. doi:10.1001/jamaoncol.2015.6487.
   PubMed Web of Science ®Google Scholar
• von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, STROBE Initiative. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344–349. doi:10.1016/j.jclinepi.2007.11.008.
   PubMed Web of Science ®Google Scholar
• Lee JJ, Feng L. Randomized phase II designs in cancer clinical trials: current status and future directions. J Clin Oncol. 2005;23(19):4450–4457. doi:10.1200/JCO.2005.03.197.
   PubMed Web of Science ®Google Scholar
• Jensen LJ, Saric J, Bork P. Literature mining for the biologist: from information retrieval to biological discovery. Nat Rev Genet. 2006;7(2):119–129. doi:10.1038/nrg1768.
   PubMed Web of Science ®Google Scholar
• Bramer GR. International statistical classification of diseases and related health problems. Tenth revision. World Health Stat Q. 1988;41:32–36.
   PubMedGoogle Scholar
• Top 50 Global Pharma Companies, Pharmaceutical Executive Ranking. 2019. https://www.rankingthebrands.com/The-Brand-Rankings.aspx?rankingID=370. Accessed: April 19, 2021.
   Google Scholar
• Saad ED, Katz A, Hoff PM, Buyse M. Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. Ann Oncol. 2010;21(1):7–12. doi:10.1093/annonc/mdp523.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457–481. doi:10.1080/01621459.1958.10501452.
   Web of Science ®Google Scholar
• Cox DR. Regression models and life-tables. J R Stat Soc Series B Stat Methodol. 1972;34(2):187–220. doi:10.1111/j.2517-6161.1972.tb00899.x.
   Web of Science ®Google Scholar
• Neyeloff JL, Fuchs SC, Moreira LB. Meta-analyses and forest plots using a microsoft excel spreadsheet: step-by-step guide focusing on descriptive data analysis. BMC Res Notes. 2012;5:52. doi:10.1186/1756-0500-5-52.
   PubMedGoogle Scholar
• Hirsch JE. An index to quantify an individual’s scientific research output. Proc Natl Acad Sci U S A. 2005;102(46):16569–16572. doi:10.1073/pnas.0507655102.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Long GV. Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials. Lancet Oncol. 2016;17(8):1037–1039. doi:10.1016/S1470-2045(16)30017-1.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. What is Cancer Immunotherapy? https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/what-is-immunotherapy.html. Accessed: April. 19, 2021.
   Google Scholar
• Johnston RJ, Comps-Agrar L, Hackney J, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell. 2014;26(6):923–937. doi:10.1016/j.ccell.2014.10.018.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Wolchok JD, Chan TA, et al. Immunotherapy: the path to win the war on cancer? Cell. 2015;161(2):185–186. doi:10.1016/j.cell.2015.03.045.
   PubMedGoogle Scholar
• Zhang Z, Luo F, Cao J, et al. Anticancer bispecific antibody R&D advances: a study focusing on research trend worldwide and in China. J Hematol Oncol. 2021;14(1):124. doi:10.1186/s13045-021-01126-x.
   PubMed Web of Science ®Google Scholar
• Aslam A, Imanullah S, Asim M, El-Menyar A. Registration of clinical trials: is it really needed? N Am J Med Sci. 2013;5(12):713–715. doi:10.4103/1947-2714.123266.
   PubMedGoogle Scholar
• Califf RM, Zarin DA, Kramer JM, Sherman RE, Aberle LH, Tasneem A. Characteristics of clinical trials registered in ClinicalTrials.gov, 2007–2010. JAMA. 2012;307(17):1838–1847. doi:10.1001/jama.2012.3424.
   PubMed Web of Science ®Google Scholar
• Connell CM, Raby S, Beh I, et al. Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes. Ann Oncol. 2017;28(7):1678–1679. doi:10.1093/annonc/mdx181.
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Howlett S, Ottaviani D, et al. Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncol. 2019;5(12):1774–1778. doi:10.1001/jamaoncol.2019.2785.
   PubMed Web of Science ®Google Scholar
• Sune P, Sune JM, Montoro JB. Positive outcomes influence the rate and time to publication, but not the impact factor of publications of clinical trial results. PLoS One. 2013;8(1):e54583. doi:10.1371/journal.pone.0054583.
   PubMed Web of Science ®Google Scholar
• Stern JM, Simes RJ. Publication bias: evidence of delayed publication in a cohort study of clinical research projects. BMJ. 1997;315(7109):640–645. doi:10.1136/bmj.315.7109.640.
   PubMed Web of Science ®Google Scholar
• Decullier E, Lheritier V, Chapuis F. Fate of biomedical research protocols and publication bias in France: retrospective cohort study. BMJ. 2005;331(7507):19. doi:10.1136/bmj.38488.385995.8F.
   PubMedGoogle Scholar
• von Elm E, Röllin A, Blümle A, Huwiler K, Witschi M, Egger M. Publication and non-publication of clinical trials: longitudinal study of applications submitted to a research ethics committee. Swiss Med Wkly. 2008;138(13–14):197–203.
   PubMed Web of Science ®Google Scholar
• Murad MH, Asi N, Alsawas M, Alahdab F. New evidence pyramid. Evid Based Med. 2016;21(4):125–127. doi:10.1136/ebmed-2016-110401.
   PubMedGoogle Scholar
• Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC. The ClinicalTrials.gov results database-update and key issues. N Engl J Med. 2011;364(9):852–860. doi:10.1056/NEJMsa1012065.
   PubMed Web of Science ®Google Scholar